 Connection
Michael Bristow to Blood Pressure
This is a "connection" page, showing publications Michael Bristow has written about Blood Pressure.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.236 |
|
|
|
-
Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation. 2003 Mar 11; 107(9):1234-6.
Score: 0.034
-
Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
Score: 0.031
-
Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
Score: 0.027
-
Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
Score: 0.026
-
Bristow MR. Mechanisms of development of heart failure in the hypertensive patient. Cardiology. 1999; 92 Suppl 1:3-6; discussion 7-9, 20-1.
Score: 0.025
-
Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DM, Quaife RA. The pressure-overloaded right ventricle in pulmonary hypertension. Chest. 1998 Jul; 114(1 Suppl):101S-106S.
Score: 0.024
-
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
Score: 0.022
-
Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
Score: 0.013
-
Shaddy RE, Mak C, Bristow MR. Comparative in vitro myocardial inotropic effects and in vivo hemodynamic effects of forskolin and isoproterenol in young lambs. Pediatr Res. 1989 Jun; 25(6):580-4.
Score: 0.013
-
Bristow MR, Sageman WS, Scott RH, Billingham ME, Bowden RE, Kernoff RS, Snidow GH, Daniels JR. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980 Sep-Oct; 2(5):487-515.
Score: 0.007
-
Moore CK, Bristow MR, Renlund DG, Rasmussen LG, O'Connell JB. Long-term morbidity of cyclosporine with corticosteroid-free maintenance immunosuppression in cardiac transplantation. Transplant Proc. 1990 Jun; 22(3 Suppl 1):25-9.
Score: 0.003
-
Renlund DG, Bristow MR, Lee HR, O'Connell JB. Medical aspects of cardiac transplantation. J Cardiothorac Anesth. 1988 Aug; 2(4):500-12.
Score: 0.003
-
Schroeder JS, Beier-Scott L, Ginsburg R, Bristow MR, McAuley BJ. Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol. 1985 Sep; 8(9):480-5.
Score: 0.003
-
Kantrowitz NE, Bristow MR, Minobe WA, Billingham ME, Harrison DC. Histamine-mediated myocardial damage in rabbits. J Mol Cell Cardiol. 1982 Sep; 14(9):551-5.
Score: 0.002
-
Ginsburg R, Bristow MR, Kantrowitz N, Baim DS, Harrison DC. Histamine provocation of clinical coronary artery spasm: implications concerning pathogenesis of variant angina pectoris. Am Heart J. 1981 Nov; 102(5):819-22.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|